Clinical trial NCT00325416: Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.
Official title: A Study of Intensive-Dose Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Multiple Myeloma
Keywords: melphalan
topotecan
topoisomerase
bone marrow transplant
drug sequence
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sponsor class: OTHER
Collaborators: name: GlaxoSmithKline
name: National Cancer Institute (NCI)
First posted: 2006-05-12
Enrollment: 177
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to determine the safest dose of topotecan when given in a high dose before a stem cell transplant; topotecan will be given with melphalan.

Detailed description: The stem cells being transplanted are cells found in the bone marrow and blood that are responsible for making red blood cells, white blood cells, and platelets. The stem cells are collected by a process called leukapheresis and will be frozen for later use. After receiving the chemotherapy drugs, the stem cells will be thawed and given like a blood transfusion. This is called autologous stem cell transplant or rescue. The study doctors will be measuring how well the disease responds to the drugs as well as any side effects to the drugs. During the course of this study, blood and bone marrow samples will be obtained to measure levels of the chemotherapy drugs as well as levels of certain enzymes (proteins).

The staff of the Blood and Marrow Transplant program will continue to collect information about the participant's disease and its treatment for the rest of their life.

Eligibility criteria: Inclusion Criteria:

* Multiple Myeloma Criteria = Newly diagnosed with drug sensitive disease (\>50% tumor response to standard chemotherapy) and poor prognostic indicators, such as Salmon-Durie stage III, serum b-2-microglobulin \>3.0 mg/L, high proliferative fraction or hypodiploidy. Relapsed patients after a response to standard chemotherapy. Patients with primary refractory disease. Patients with non-secretory multiple myeloma are eligible for enrollment on this study. They will be followed for toxicity, survival and molecular endpoint analyses, but will not be followed for response. Patients with plasma cell leukemia, either occurring de novo or arising from existing multiple myeloma, are ineligible for this study.
* Patients greater than or equal to 18 years of age are eligible.
* Patients must have histologically confirmed diagnosis by a pathologic review at the H. Lee Moffitt Cancer Center and Research Institute.
* Patients must have undergone a complete psychosocial evaluation and been considered capable of compliance.
* Patients willing and able to receive palifermin (young cohort only)

Exclusion Criteria:

* Patients with a diffusing lung capacity oxygenation (DLCO) less than 50% (adjusted) of normal or with symptomatic obstructive or restrictive disease are ineligible.
* Patients with a serum creatinine of greater than 2.0 mg/dL OR a creatinine clearance of less than 40 ml/minute. Creatinine clearance can be measured or calculated. Patients with renal dysfunction secondary to multiple myeloma may be enrolled at the discretion of the principal investigator. However, patients on hemodialysis or peritoneal dialysis are ineligible.
* Patients with a total bilirubin greater than 2.0 mg/dL and serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) greater than two and a half times normal (unless due to primary malignancy), or a history of severe hepatic dysfunction are ineligible.
* Patients who have evidence of severe cardiac dysfunction are ineligible. A gated blood pool (MUGA) scan must show an ejection fraction of at least 50%. Patients must be free of major heart disease. Patients are ineligible if they have received a total dose of doxorubicin of greater than 450 mg/m2 (or daunorubicin equivalent) unless the left ventricular ejection fraction by MUGA scan is at least 50%. Patients must not be taking nitroglycerin preparations for angina pectoris or antiarrhythmic drugs for major ventricular dysrhythmias. Patients with essential hypertension controlled with medications are eligible for study. Any patient with congenital or acquired heart disease or cardiac arrhythmias will have a cardiology consult and evaluation.
* Patients with active infections are ineligible.
* Patients who are HIV antibody positive are ineligible.
* Patients with active leptomeningeal involvement are ineligible. Patients with a history of previous cerebrospinal fluid (CSF) tumor involvement without symptoms or signs are eligible provided the CSF is now free of disease on lumbar puncture and MRI of the brain shows no tumor involvement. Patients with severe symptomatic central nervous system (CNS) disease of any etiology are ineligible.
* Patients with uncontrolled insulin-dependent diabetes mellitus or uncompensated major thyroid or adrenal dysfunction are ineligible.
* Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of \> or = 2 are ineligible. Patients with ECOG performance status 2 to 3 secondary to bone pain may be enrolled at the discretion of the institutional investigator. Patients with ECOG performance status 2 to 3 secondary to a potentially reversible disease-related problem may be enrolled at the discretion of the institutional investigator.
* Patients who are pregnant or lactating are ineligible.
* Patients with any previous malignancy other than non-melanoma skin cancer are ineligible, unless the patient is without evidence of disease \> or = 5 years after the treatment for the cancer was completed.
* Patients previously treated with topotecan or any other topoisomerase I inhibitor.

Primary outcomes:
measure: Phase I - Maximum Tolerated Dose (MTD) Level
timeFrame: Phase I - 5 years, 2 months
measure: Phase II Participants - Overall Response Rate
timeFrame: Phase II - Phase start at 62 months up to 120 months
Secondary outcomes:
measure: Phase II Event Free Survival (EFS)
timeFrame: Phase II - Phase start at 62 months up to 120 months
measure: Phase II Overall Survival (OS)
timeFrame: Phase II - Phase start at 62 months up to 120 months
Other outcomes:
measure: Pharmacokinetic Profiles of High Dose Topotecan and Melphalan
timeFrame: Predetermined time points in protocol
measure: Amount, Activity and Subcellular Distribution of Topoisomerase I With Clinical Response and Toxicity
timeFrame: Laboratory study (no specific time points)
measure: DNA Topoisomerase I Amount, Activity, or Subcellular Distribution
timeFrame: Laboratory study (N/A)
measure: Genomic DNA Sequence Variations and Correlate With Toxicity to Melphalan and Topotecan
timeFrame: Laboratory study (N/A)
measure: Breast Cancer Resistance Protein (BCRP) Expression
timeFrame: Laboratory study (N/A)
Locations:
city: Tampa
country: United States
facility: H. Lee Moffitt Cancer Center & Research Institute
state: Florida
Study officials:
affiliation: H. Lee Moffitt Cancer Center and Research Institute
name: Daniel M Sullivan, MD
role: PRINCIPAL_INVESTIGATOR
References: